9CCI

Dissecting human monoclonal antibody responses from mRNA and protein-based booster vaccinations against XBB1.5 SARS-CoV-2

9CCI の概要

• エントリーDOI: 10.2210/pdb9cci/pdb
• EMDBエントリー: 45443 45444
• 分子名称: M39 Fab heavy chain, Spike glycoprotein, M39 Fab light chain, ... (4 entities in total)
• 機能のキーワード: sars-cov-2, antibody, rbd, immune system, virus like particle, viral protein-immune system complex, viral protein/immune system
• 由来する生物種: Homo sapiens; 詳細
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 185617.21

構造登録者

Bajic, G.,Jaiswal, D. (登録日: 2024-06-21, 公開日: 2025-03-12, 最終更新日: 2025-08-20)

主引用文献

Fantin, R.F.,Clark, J.J.,Cohn, H.,Jaiswal, D.,Bozarth, B.,Rao, V.,Civljak, A.,Lobo, I.,Nardulli, J.R.,Srivastava, K.,Yong, J.S.,Andreata-Santos, R.,Bushfield, K.,Lee, E.S.,Singh, G.,Kleinstein, S.H.,Krammer, F.,Simon, V.,Bajic, G.,Coelho, C.H.
Mapping of human monoclonal antibody responses to XBB.1.5 COVID-19 monovalent vaccines: a B cell analysis.
Lancet Microbe, 6:101103-101103, 2025

PubMed Abstract: The rapid emergence of highly transmissible and immune-evasive SARS-CoV-2 variants has required the reformulation of COVID-19 vaccines to target these evolving threats. Although previous infections and booster vaccinations can boost variant neutralisation, it remains uncertain whether monovalent vaccines-delivered via mRNA or protein-based platforms-can trigger novel B-cell responses specific to omicron XBB.1.5 variants. We sought to address this uncertainty by characterising the antibody repertoire of individuals receiving a monovalent booster vaccine.

PubMed: 40456237
DOI: 10.1016/j.lanmic.2025.101103

実験手法

ELECTRON MICROSCOPY (2.65 Å)